MicroPort® NeuroTech（Shanghai）Co., Ltd.

News

2022-08-27

MicroPort NeuroTech™ Announces 2022 Interim Results

Shanghai, China, 27 August 2022 – MicroPort NeuroTech Limited (“MicroPort NeuroTech™” or the “Company”) today announced the interim results of the Company and its subsidiaries for the six months ended 30 June 2022 (the “Reporting Period”).
2022-08-27

MicroPort NeuroTech™ NUMEN Coil Embolization System Receives Marketing Approval in Japan

Tokyo, Japan, 22 August 2022 – MicroPort Neurotech Limited (“MicroPort NeuroTech™”), a pioneering Chinese company in the field of neurovascular interventional treatment, today announced that it has received marketing approval issued by Ministry of Health, Labour and Welfare Japan for its independently-developed Numen™ Coil Embolization System (“Numen™”), marking the first approved product in Japan for MicroPort NeuroTech™.
2022-08-25

MicroPort NeuroTech™ Completes First Implantations of NUMEN™ Coil Embolization System in Poland

Krakow/Kielce, Poland, 10 August 2022 — MicroPort Neurotech Limited (“MicroPort NeuroTech™”) recently announced that its independently developed Numen™ Coil Embolization System (“Numen™”) has been successfully used in the first two implantations in Poland. Numen™’s deliverability and detac
2022-07-15

MicroPort NeuroTech™ Debuts on Main Board of HKEX

As the Pioneer & Largest Chinese Player in the Neuro-interventional Medical Device Industry.
2022-06-28

MicroPort NeuroTech™ Completes First Implantation of Numen™ Coil Embolization System in the U.S.

Boston, United States/Shanghai, China, 28 June 2022 - MicroPort Neurotech Limted (hereafter referred to as “MicroPort NeuroTech™” of the “Company”), a pioneering Chinese company in the field of neurovascular interventional treatment, today announced it has successfully completed the first comm.
2022-04-22

MicroPort NeuroTech™ Receives NMPA Marketing Approval for the X-track™ Intracranial Distal Access Catheter

The approved X-track™ is made of special polymer materials and a braided structure with two filaments that can reach the lesion site repeatedly during the procedure.
2022-03-11

MicroPort NeuroTech™ Receives NMPA Marketing Approval for its NUMEN Silk^® 3-D Coil Embolization System

MicroPort NeuroTech™ Receives NMPA Marketing Approval for its NUMEN Silk^® 3-D Coil Embolization System.
2022-03-04

MicroPort NeuroTech™ NUMEN^® Coil Embolization System Listed for Reimbursement under Korea’s National Health Insurance System

MicroPort NeuroTech™ NUMEN® has been approved for entry into the Korean health insurance scheme and for inclusion into the reimbursement list. This means that NUMEN^® is not only approved for use in Korean hospitals, but also reimbursable under the national health insurance program.
2022-03-01

MicroPort NeuroTech™ Obtains NMPA Marketing Approval for its Neurohawk^® Stent Thrombectomy Device

self-expandable clot stent retriever used in endovascular invasive thrombectomy procedures to remove large clots in blood vessels. During the procedure, Neurohawk® is delivered by a microcatheter within the vessel lumen and released at the targeted clot. This allows its mesh structure to penetrate and engage the clot, which is removed along with stent retrieving, allowing for quick restoration of blood flow.
2022-03-01

MicroPort NeuroTech™ Receives NMPA Marketing Approval for its NUMEN Silk^® 3-D Coil Embolization System

MicroPort NeuroTech Limited has received marketing approval from China’s National Medical Products Administration (NMPA) for its independently-developed NUMEN Silk^® 3-D Electronically Detachable Coil Embolization System (NUMEN Silk^® ).

1 2 3

上一页 1/3 下一页

手机：

(86)19542912295

电话：

(86) (21)38954600-55200

地址：

1661 Zhangdong Road, Zhangjiang High-tech Park, Pudong New District, Shanghai, PRC

传真：

(21) 50801305

关于我们

患者关怀

投资者关系

人才中心

新闻资讯

|

Copyright 2019 MicroPort® NeuroTech（Shanghai）Co., Ltd. 沪ICP备19033024号-1 微信图片_20200506140817.png 沪公网安备 31011502014931号